Anthelmintics are drugs that either kill (vermicide)
or expel (vermifuge) infesting helminths.
Helminthiasis is prevalent globally , but is more
common in developing countries with poorer
personal and environmental hygiene. Multiple
infestations in the same individual are not
infrequent. In the human body, g.i.t. is the abode
of many helminths, but some also live in tissues,
or their larvae migrate into tissues.
They harm the host by depriving him of food, causing
blood loss, injury to organs, intestinal or
lymphatic obstruction and by secreting toxins.
Helminthiasis is rarely fatal, but is a major cause
of ill health.
The choice of drug for each worm infestation
is based not only on efficacy, but also on lack
of side effects/toxicity, ease of administration
(preferably single dose) and low cost. Development
of resistance has not been a problem in
the clinical use of anthelmintics.
The antibiotics, important considerations for their use, their classification, synergistic and antagonistic effect, hypersensitivity reactions and development of resistance to these agents.
Antimalarial drug efficacy and drug resistance(yemen)Ghamdan Al Tahish
Antimalarial drug efficacy
Antimalarial drug resistance
Treatment failure
Emergence and spread of resistance to antimalarial drugs
Monitoring antimalarial drug efficacy and drug resistance
Criteria for antimalarial treatment policy change
The old antimalarial drug policy in Yemen
Monitoring the efficacy of AMDs in Yemen 2002-2005
Monitoring antimalarial drug efficacy and drug resistance in Yemen 2009-2010
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Recombinant monoclonal antibody against mouse and human CXCL12α, CXCL12β, and CXCL12γ, was shown to dose-dependently block CXCL12α binding to CXCR4 and CXCR7, and CXCL12α-induced Jurkat cell migration in vitro.
Anthelmintics are drugs that either kill (vermicide)
or expel (vermifuge) infesting helminths.
Helminthiasis is prevalent globally , but is more
common in developing countries with poorer
personal and environmental hygiene. Multiple
infestations in the same individual are not
infrequent. In the human body, g.i.t. is the abode
of many helminths, but some also live in tissues,
or their larvae migrate into tissues.
They harm the host by depriving him of food, causing
blood loss, injury to organs, intestinal or
lymphatic obstruction and by secreting toxins.
Helminthiasis is rarely fatal, but is a major cause
of ill health.
The choice of drug for each worm infestation
is based not only on efficacy, but also on lack
of side effects/toxicity, ease of administration
(preferably single dose) and low cost. Development
of resistance has not been a problem in
the clinical use of anthelmintics.
The antibiotics, important considerations for their use, their classification, synergistic and antagonistic effect, hypersensitivity reactions and development of resistance to these agents.
Antimalarial drug efficacy and drug resistance(yemen)Ghamdan Al Tahish
Antimalarial drug efficacy
Antimalarial drug resistance
Treatment failure
Emergence and spread of resistance to antimalarial drugs
Monitoring antimalarial drug efficacy and drug resistance
Criteria for antimalarial treatment policy change
The old antimalarial drug policy in Yemen
Monitoring the efficacy of AMDs in Yemen 2002-2005
Monitoring antimalarial drug efficacy and drug resistance in Yemen 2009-2010
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Recombinant monoclonal antibody against mouse and human CXCL12α, CXCL12β, and CXCL12γ, was shown to dose-dependently block CXCL12α binding to CXCR4 and CXCR7, and CXCL12α-induced Jurkat cell migration in vitro.
Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-terminal epitope with F37 and G33 being the most important residues. G1 does not bind to CGRP when an extra amino acid residue (alanine) is added at the C-terminal.
Anti-CGRP Antagonist Antibody scFv fragment G1 binds to a C-terminal epitope with F37 and G33 being the most important residues. G1 does not bind to CGRP when an extra amino acid residue (alanine) is added at the C-terminal.
This antibody is a rat monoclonal antibody that binds specifically to mouse CX3CL1/Fractalkine, and it can neutralize the bioactivity of mouse CX3CL1/Fractalkine.
Recombinant Human Antibody (dAb HEL4) is capable of binding to Chicken LYZ, expressed in HEK 293 cells. Expressed as the combination of a heavy chain (HC) containing VH from anti-Chicken LYZ mAb and CH1-3 region of human IgG1 and a light chain (LC) encoding VL from anti-Chicken LYZ mAb and CL of human kappa light chain. Exists as a disulfide linked dimer of the HC and LC hetero-dimer under non-reducing condition. HEL4 is highly soluble at concentrations of> or =3 mM, essentially monomeric and resistant to aggregation upon thermodenaturation at concentrations as high as 56 microM.
Recombinant monoclonal antibody to CD70. VL-8-VH is a human antibody that can be potentially used in the treatment of autoimmune and inflammatory disease.
Untargeted metabolomics, namely discovery metabolomics, involves the comparison of the metabolome between the control and test groups, to identify differences between their metabolite profiles which may be relevant to specific biological conditions.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to IL2. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of IL2. under in vitro conditions, IL2-FuP efficiently initiated T-cell activation and stimulated LAKs as well as CTLs. Its potency was superior but not qualitatively different from that of a mixture of anti-EGFR and IL2 This immunocytokine was designed for treating Hodgkin's lymphoma.
MDX-1401 is a fully human, non-fucosylated antibody that targets CD30, a marker for activated lymphocytes that is present on malignant cells of HL as well as other CD30-expressing cancers.
CCR2, which is a receptor for the C-C chemokines can bind MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. CCR2 as well as processes and cellular responses mediated by CCR2, are involved in rejection of transplanted grafts
CCR2, which is a receptor for the C-C chemokines can bind MCP-1, MCP-2, MCP-3, MCP-4 and MCP-5. CCR2 as well as processes and cellular responses mediated by CCR2, are involved in rejection of transplanted grafts.
Provided is an anti-human CD40 antibody that is substantially antagonistic to a human CD40 antigen on the dendritic cell (DC) surface. And it is an agonistic anti-human CD40 antibody that is expected to have a therapeutic effect higher than those of conventional anti-human CD40 antibodies.
This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD3 IgG to TNF. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD3 as well as the biological activity of TNF. TNF-FuP provided a weak stimulus for lymphocyte proliferation, but it had no effect on LAK cells. However, it supported activation of Mfs and, to a minor extent, of CTLs. This immunocytokine was designed for treating CD30-positive lymphoma.
The present antibody specifically binds to CD38 which is capable of killing a CD38+ cell by induction of apoptosis, antibody-dependent cell- mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity. The disclosed antibody may be used as a medicament or in the making of a medicament, wherein the antibody is to be administered to a human subject in a safe therapeutic dose.
Recombinant Chimeric (Human/Mouse) Antibody (CHI621) is capable of binding to CD25, expressed in Chinese Hamster Ovary cells (CHO). This chimeric antibody (SDZ CHI621) has been evaluated in a phase I/II clinical study in human renal cadaver transplantation and has shown very promising results.
This presentation explores a brief idea about the structural and functional attributes of nucleotides, the structure and function of genetic materials along with the impact of UV rays and pH upon them.
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Comparing Evolved Extractive Text Summary Scores of Bidirectional Encoder Rep...University of Maribor
Slides from:
11th International Conference on Electrical, Electronics and Computer Engineering (IcETRAN), Niš, 3-6 June 2024
Track: Artificial Intelligence
https://www.etran.rs/2024/en/home-english/
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...Ana Luísa Pinho
Functional Magnetic Resonance Imaging (fMRI) provides means to characterize brain activations in response to behavior. However, cognitive neuroscience has been limited to group-level effects referring to the performance of specific tasks. To obtain the functional profile of elementary cognitive mechanisms, the combination of brain responses to many tasks is required. Yet, to date, both structural atlases and parcellation-based activations do not fully account for cognitive function and still present several limitations. Further, they do not adapt overall to individual characteristics. In this talk, I will give an account of deep-behavioral phenotyping strategies, namely data-driven methods in large task-fMRI datasets, to optimize functional brain-data collection and improve inference of effects-of-interest related to mental processes. Key to this approach is the employment of fast multi-functional paradigms rich on features that can be well parametrized and, consequently, facilitate the creation of psycho-physiological constructs to be modelled with imaging data. Particular emphasis will be given to music stimuli when studying high-order cognitive mechanisms, due to their ecological nature and quality to enable complex behavior compounded by discrete entities. I will also discuss how deep-behavioral phenotyping and individualized models applied to neuroimaging data can better account for the subject-specific organization of domain-general cognitive systems in the human brain. Finally, the accumulation of functional brain signatures brings the possibility to clarify relationships among tasks and create a univocal link between brain systems and mental functions through: (1) the development of ontologies proposing an organization of cognitive processes; and (2) brain-network taxonomies describing functional specialization. To this end, tools to improve commensurability in cognitive science are necessary, such as public repositories, ontology-based platforms and automated meta-analysis tools. I will thus discuss some brain-atlasing resources currently under development, and their applicability in cognitive as well as clinical neuroscience.
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...Scintica Instrumentation
Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes.
In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies.
Professional air quality monitoring systems provide immediate, on-site data for analysis, compliance, and decision-making.
Monitor common gases, weather parameters, particulates.